Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Update

Cellebrite DI Ltd. (NASDAQ:CLBT) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 2,480,000 shares, a decline of 5.3% from the March 15th total of 2,620,000 shares. Based on an average daily volume of 998,300 shares, the short-interest ratio is presently 2.5 days. Currently, 4.5% of the shares of the stock are sold short.

Cellebrite DI Trading Down 1.1 %

NASDAQ:CLBT opened at $10.38 on Thursday. Cellebrite DI has a 12 month low of $5.22 and a 12 month high of $12.50. The stock has a 50 day moving average of $11.19 and a two-hundred day moving average of $9.16.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. Cellebrite DI had a positive return on equity of 173.14% and a negative net margin of 24.94%. The company had revenue of $93.01 million during the quarter, compared to analyst estimates of $85.43 million. On average, sell-side analysts expect that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

A number of large investors have recently made changes to their positions in CLBT. UBS Group AG purchased a new stake in shares of Cellebrite DI in the first quarter valued at approximately $26,000. Virtus Fund Advisers LLC purchased a new stake in shares of Cellebrite DI in the fourth quarter valued at approximately $28,000. Parallel Advisors LLC grew its position in shares of Cellebrite DI by 75.0% in the fourth quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after purchasing an additional 1,500 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Cellebrite DI in the fourth quarter valued at approximately $32,000. Finally, Steward Partners Investment Advisory LLC grew its position in shares of Cellebrite DI by 81.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,784 shares of the company’s stock valued at $34,000 after purchasing an additional 3,494 shares in the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. William Blair upgraded Cellebrite DI from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 13th. Bank of America lifted their price target on Cellebrite DI from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Needham & Company LLC lifted their price target on Cellebrite DI from $13.00 to $13.50 and gave the company a “buy” rating in a research note on Thursday, March 28th. Finally, Craig Hallum lifted their price target on Cellebrite DI from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $12.30.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.